arrow
E

Eugeni Domènech

Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas
H指数:51
被引数:8,644

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics, management, and long-term outcomes of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease: Data from the ENEIDA registry

炎症性肠病中坏疽性脓皮病和结节性红斑的特征、管理及长期结局:ENEIDA登记研究数据

2026-11-030
PRE
Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry

炎症性肠病未分类患者的结局与再分类模式:一项与西班牙ENEIDA登记系统中溃疡性结肠炎患者匹配的多中心研究

2026-09-230
OAAI
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

先前生物制剂作用机制对炎症性肠病中抗TNF疗效的影响:一项ENEIDA注册研究

2026-08-120
PREAI
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

真实世界中乌帕替尼治疗克罗恩病的有效性与安全性:来自Eneida注册研究的启示

2026-04-300
OAAI
Interpretable inflammation landscape of circulating immune cells

循环免疫细胞的可解释性炎症景观

2026-01-120
OAAI
Dialister-driven succinate accumulation is associated with disease activity and postoperative recurrence in Crohn's disease

Dialister驱动的琥珀酸盐积累与克罗恩病的疾病活动性和术后复发相关。

2025-12-070
PRE
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry

老年患者术后克罗恩病的治疗管理及预后比较研究:ENEIDA登记研究数据

2025-12-010
OAAI
Uncovering combination therapies for Immune-Mediated Inflammatory Diseases through systems biology analysis on longitudinal patient data
2025-11-010
PRE
Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU
2025-11-010
PRE
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicity

硫嘌呤毒性的新见解:稀有XDH变异体对骨髓毒性的贡献

2025-08-130
PREAI
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

自然病史、免疫学和遗传学特征,以及临床前期炎症性肠病(EARLY)的研究方案:一项前瞻性队列研究

2025-05-120
OA
Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

有家族炎症性肠病史对生物制剂治疗时代儿童起病炎症性肠病患者免疫抑制剂、生物制剂使用及手术的影响。ENEIDA注册研究的结果。

2025-05-120
OA
Time-trends in the management of postoperative Crohn's Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry
2025-01-220
PRE
Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
2025-01-220
PRE
Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn's Disease. Data from the ENEIDA registry
2025-01-220
PRE
Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCU
2025-01-220
PRE